Both in R&D — Physical & Biological Sciences
Incyte Genomics vs Medpace Holdings
Over the past year INCY returned +48.8% and MEDP returned +23.0%; their daily moves had a correlation of 0.32.
INCY +48.8% MEDP +23.0%Growth of $1, one year, split-adjusted
| Metric | INCY | MEDP |
|---|---|---|
| Price | $124.82 | $615.94 |
| Market cap | $25.30B | $17.19B |
| Today | +0.75% | −0.48% |
| 1 month | −2.3% | +0.7% |
| 6 months | +38.2% | +36.5% |
| Year to date | +26.4% | +9.7% |
| 1 year | +52.9% | +26.2% |
| Revenue growth (YoY) | +37.7% | +17.2% |
| Gross margin | 93.7% | 28.5% |
| Net margin | 35.0% | 17.2% |
| P/E (TTM) | 15.7× | 35.0× |
| Price / sales | 4.3× | 6.2× |
| Net cash | $4.50B | $502.7M |
| Dividend yield | — | — |
| Volatility (60d) | 30.4% | 37.1% |
| Short % of float | 6.0% | 7.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).